Eden Research (EDEN)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

4.25p
   
  • Change Today:
    -0.100p
  • 52 Week High: 11.85
  • 52 Week Low: 3.40
  • Currency: UK Pounds
  • Shares Issued: 533.35m
  • Volume: 372,801
  • Market Cap: £22.67m

Eden Research confirms emergency use authorisation for 'Cedroz' in Italy

By Josh White

Date: Friday 26 Apr 2019

LONDON (ShareCast) - (Sharecast News) - Biopesticide developer Eden Research announced on Friday that its commercial partner, Eastman Chemical Company, has received a 120-day 'emergency use' authorisation for its nematicide formulation, marketed as 'Cedroz' by Eastman, from the Italian Ministry of Agriculture.
The AIM-traded firm said such emergency authorisations were allowed by EU member states when local regulatory authorities judged that they are needed in the local market in order to meet the requirements of growers in the absence of suitable commercially-available alternatives.

During the period, Italy and other member states would continue to process Eastman's request for the authorised use and sale of Cedroz following Malta's earlier authorisation.

Cedroz was described by Eden Research as an "innovative and sustainable" solution designed to fight plant parasitic nematodes - pests that are known to cause severe damage to crops globally in both open field and greenhouse horticulture - resulting in significant yield losses and increasing growers' costs.

In line with consumer demand and a policy push for products that supported sustainable agriculture with greatly reduced or no pesticide residues, the firm said Cedroz was an "attractive alternative" for farmers looking to fight plant parasitic nematodes in a safer and more sustainable way.

Unlike many other products, Cedroz would have no set maximum residue level and a zero-day pre-harvest interval, thereby allowing applications right up to harvest, when required.

As the company had previously announced, Malta recently authorised the use of Cedroz on a wide range of crops, including cucumbers, courgettes, melons, aubergine, peppers, tomatoes and strawberries, marking the initial authorisation for Cedroz in the EU.

Following the authorisation by Malta, the concerned Member States became required to grant their individual approvals for the sale and use of Cedroz within their jurisdictions.

The pending approvals would cover Spain and Italy, for outdoor uses, and would also cover France, Belgium, the Netherlands and the United Kingdom, as well as Spain and Italy, for professional greenhouse uses.

Once approved, Cedroz would be the first of Eden's formulations to be sold and used in the United Kingdom, where the company is headquartered.

"Following Eden's initial investment in the formulation and patent protection of this important product, Eastman has invested significant resource over the past three years in the further development of Cedroz, and it is pleasing to see our collective efforts coming to fruition," said Eden Research chief executive officer Sean Smith.

"Traditional crop protection products are increasingly coming under threat from global regulatory pressures based upon the potential impact these products may have on the environment.

"There is significant and increasing demand for biopesticides as alternatives to conventional pesticide treatments due to their health and environmental safety profiles."

Smith said the company was "looking forward" to working with Eastman to capitalise on the growing demand and helping them to launch Cedroz in a number of new territories, including the UK.

"The Italian market represents a significant opportunity for Cedroz and, as such, it is great to see the regulatory authorities respond positively by granting this emergency authorisation.

"This also verifies that there is a limited number of alternative products available to tackle nematodes in the Italian market and consequently growers need new tools to help control this damaging pest on a range of important high value crops."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Eden Research Market Data

Currency UK Pounds
Share Price 4.25p
Change Today -0.100p
% Change -2.30 %
52 Week High 11.85
52 Week Low 3.40
Volume 372,801
Shares Issued 533.35m
Market Cap £22.67m

Eden Research Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
28.67% below the market average28.67% below the market average28.67% below the market average28.67% below the market average28.67% below the market average
54.39% above the sector average54.39% above the sector average54.39% above the sector average54.39% above the sector average54.39% above the sector average
Income Not Available
Growth
5.39% above the market average5.39% above the market average5.39% above the market average5.39% above the market average5.39% above the market average
8.11% above the sector average8.11% above the sector average8.11% above the sector average8.11% above the sector average8.11% above the sector average

Eden Research Dividends

No dividends found

Trades for 25-Apr-2024

Time Volume / Share Price
16:24 47,214 @ 4.26p
16:23 2,500 @ 4.28p
16:12 50,000 @ 4.26p
14:41 160,000 @ 4.32p
13:11 614 @ 4.32p

Eden Research Key Personnel

CFO Alexander John Abrey
CEO Sean M. Smith

Top of Page